NEMIO研究:ddMVAC联合度伐利尤单抗±替西木单抗新辅助治疗肌层浸润性膀胱癌
NEMIO是一项多中心随机非比较II期试验,评估ddMVAC联合度伐利尤单抗±替西木单抗在肌层浸润性膀胱癌新辅助治疗中的疗效与安全性。双药组pCR率为48.70%,三药组为46.27%;双药组≥3级TRAE为30.48%,三药组为49.63%。结论认为ddMVAC联合度伐利尤单抗pCR令人鼓舞、早期生存良好、安全性可控,加用替西木单抗pCR相似但毒性更差。
要点
- ddMVAC联合度伐利尤单抗新辅助治疗MIBC的pCR率达48.70%,达到预设阳性阈值。
- 加用替西木单抗未提高pCR(46.27%),但≥3级TRAE从30.48%升至49.63%。
- 探索性分析显示PD-L1高表达肿瘤pCR率68.25%,低/阴性为33.49%。
核心结论
- 新辅助ddMVAC联合度伐利尤单抗在肌层浸润性膀胱癌中显示令人鼓舞的pCR率和可控安全性。
- 加用替西木单抗pCR相似但毒性更差,不支持三药联合方案。
- 结果支持ddMVAC联合度伐利尤单抗作为新辅助化疗免疫策略进一步开展对照试验。
研究设计与样本
- NEMIO为多中心、随机、非比较II期试验(NCT03549715),纳入cT2-T4a N0-1顺铂合格拟行根治性膀胱切除术的MIBC患者。
- 患者接受ddMVAC每2周×4周期,联合度伐利尤单抗±替西木单抗每4周×2次(C1D1和C3D1),随后行根治性膀胱切除术。
- 共119例患者接受治疗(双药组60例,三药组59例),113例接受根治性膀胱切除术。
- 共同主要终点为局部评估的病理完全缓解(pCR;ypT0N0)和≥3级治疗相关不良事件(TRAE)率。
- 研究阳性标准为pCR率≥45%且≥3级TRAE率≤30%。
主要发现
- 总体贝叶斯后验平均pCR率双药组为48.70%(95%CI 35.93-61.56),三药组为46.27%(95%CI 33.92-58.85)。
- 在103例有PD-L1数据的患者中(探索性),PD-L1高表达肿瘤贝叶斯后验平均pCR为68.25%(95%CI 54.57-80.49),PD-L1低/阴性为33.49%(95%CI 22.13-45.91)。
- 贝叶斯后验平均≥3级TRAE总体为40.95%(95%CI 32.50-49.69);双药组30.48%(95%CI 20.00-42.08),三药组49.63%(95%CI 37.55-61.73)。
- 免疫相关不良事件发生率为26.9%(≥3级4.2%)。
- 双药组2年无事件生存率和总生存率分别为75%和85%,三药组分别为77%和88%。
关键数值与推荐
- pCR定义为ypT0N0(局部评估)。
- 研究阳性阈值:pCR率≥45%且≥3级TRAE率≤30%。
- ddMVAC方案剂量:顺铂70 mg/m2、甲氨蝶呤30 mg/m2、多柔比星30 mg/m2、长春碱3 mg/m2(第1天),培非格司亭6 mg(第2天)。
- 度伐利尤单抗1500 mg,替西木单抗75 mg,每4周×2次(C1D1和C3D1)。
临床怎么用
- 新辅助ddMVAC联合度伐利尤单抗可作为肌层浸润性膀胱癌的候选化疗免疫策略,pCR率接近50%。
- 不推荐在ddMVAC联合度伐利尤单抗基础上常规加用替西木单抗,因毒性明显增加而pCR无改善。
- PD-L1高表达患者可能从该方案获得更高pCR率,但证据为探索性,尚不能用于常规分层。
局限性
- 本研究为随机非比较II期试验,未设标准治疗对照,无法直接比较联合方案与单纯化疗的优劣。
- PD-L1分析为探索性,样本量有限(103例),结果需前瞻性验证。
- 随访时间较短,2年生存数据为早期结果,长期生存获益尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) combined with durvalumab ± tremelimumab in patients with muscle-invasive bladder cancer (MIBC). METHODS: NEMIO (ClinicalTrials.gov identifier: NCT03549715) is a multicenter, randomized, noncomparative phase II trial in cT2-T4a N0-1 cisplatin-eligible MIBC planned for radical cystectomy (RC). Patients received ddMVAC (cisplatin 70 mg/m2, methotrexate 30 mg/m2, doxorubicin 30 mg/m2, and vinblastine 3 mg/m2 on days 1, and pegfilgrastim 6 mg on days 2) once every 2 weeks × four cycles plus durvalumab ± tremelimumab (durvalumab 1,500 mg and tremelimumab 75 mg) once every 4 weeks × two doses (C1D1 and C3D1) before RC. Coprimary end points (local assessment) were pathologic complete response (pCR; ypT0N0) and grade ≥3 treatment-related adverse events (TRAEs). The study was considered positive if the pCR rate was ≥45% and the rate of grade ≥3 TRAEs was ≤30%. RESULTS: From 2018 to 2022, 119 patients received ddMVAC + durvalumab (n = 60) or ddMVAC + durvalumab + tremelimumab (n = 59); 113 underwent RC. The overall Bayesian posterior mean pCR rate was 48.70% (95% CI, 35.93 to 61.56) with doublet and 46.27% (95% CI, 33.92 to 58.85) with triplet. Among 103 patients with PD-L1 data (exploratory), Bayesian posterior mean pCR was 68.25% (95% CI, 54.57 to 80.49) in PD-L1-high tumors versus 33.49% (95% CI, 22.13 to 45.91) in PD-L1-low/negative tumors. Bayesian posterior mean grade ≥3 TRAEs occurred in 40.95% (95% CI, 32.50 to 49.69) overall (30.48% [95% CI, 20.00 to 42.08] doublet; 49.63% [95% CI, 37.55 to 61.73] triplet); immune-related adverse events occurred in 26.9% (grade ≥3 4.2%). Two-year event-free survival and overall survival rates were 75% and 85% in the doublet arm, and 77% and 88% in the triplet arm, respectively. CONCLUSION: Neoadjuvant ddMVAC plus durvalumab demonstrated encouraging pCR rates, favorable early survival outcomes, and manageable safety profile. Adding tremelimumab provides similar pCR but worse toxicity. These results support further study of ddMVAC plus durvalumab as a neoadjuvant chemoimmunotherapy strategy for localized MIBC, to be evaluated in comparative trials within an evolving perioperative treatment landscape.
引用
- Thibault C, Bennamoun M, Fléchon A, et al. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study. J Clin Oncol. 2026. PMID: 42190158. doi:10.1200/JCO-25-03045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。